BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge’s losses widened as R&D spending surged, but cash runway remains strong through 2029.

What the company is saying

BioAge Labs, Inc. positions itself as a clinical-stage biopharma innovator targeting cardiometabolic diseases via aging biology, with BGE-102 as its lead candidate. The company highlights the potential of BGE-102, citing Phase 1 data showing up to 98% suppression of IL-1β and 86% median hsCRP reduction, and emphasizes recent clinical progress: first patient dosed in the QUELL-DME Phase 2 trial for diabetic macular edema in September 2026 and full enrollment of the QUELL-CV cardiovascular Phase 2 trial. CEO Kristen Fortney frames BGE-102 as potentially best-in-class and stresses the significance of its tissue penetration and tolerability profile. The narrative underscores robust R&D activity, including APJ agonist programs and milestones in collaborations with Novartis, Lilly ExploR&D, and Deep Origin. The company explains the sharp drop in collaboration revenue as a result of a $1.7 million cumulative catch-up adjustment tied to a September 2026 Novartis agreement amendment. Management asserts confidence in its $352.3 million cash position, projecting operational funding through 2029.

What the data suggests

Collaboration revenue for Q3 2026 fell to $0.3 million from $2.1 million in Q3 2025, a $1.8 million decline driven by a $1.7 million catch-up adjustment from the Novartis agreement amendment. Research and development expenses rose sharply to $30.2 million from $18.5 million, with $13.2 million of the increase attributed to BGE-102 clinical trial and manufacturing costs, and $1.7 million to personnel-related expenses; this was partially offset by a $3.3 million reduction in other program costs. General and administrative expenses increased to $7.5 million from $6.7 million, mainly due to a $1.2 million rise in personnel costs and $0.2 million in consulting fees, offset by a $0.6 million drop in legal fees. Net loss widened to $33.5 million ($0.73 per share) from $20.2 million ($0.56 per share) year-over-year. Cash, cash equivalents, and marketable securities stood at $352.3 million as of September 30, 2026, with management stating this is sufficient to fund operations through 2029. The company has achieved key clinical milestones, including dosing the first participant in a major Phase 2 trial and completing enrollment in another, but topline data for these programs are not expected until late 2026 or 2027. The financial trajectory is negative, with rising losses and burn rate, but the cash position is currently robust.

Analysis

The announcement is measured and factual, providing detailed financial results, clinical trial milestones, and partnership updates. Most claims are realised and supported by specific data, such as the dosing of the first participant in the QUELL-DME Phase 2 trial, completion of enrollment in QUELL-CV, and financial figures for revenue, expenses, and cash position. Forward-looking statements (e.g., anticipated topline results in 2026/2027, intent to file an IND, cash runway through 2029) are clearly identified and not overstated. The company is incurring high R&D expenses ($30.2 million for the quarter) with no near-term revenue prospects, and topline clinical results are at least several quarters away, indicating a long execution distance and high capital intensity. However, the tone remains neutral, and there is no narrative inflation or exaggerated language relative to the evidence. The gap between narrative and reality is minimal, with the main risk being the long timeline to potential value inflection.

Risk flags

• ●BioAge’s net loss increased to $33.5 million for the quarter, reflecting a substantial rise in R&D and G&A expenses. This burn rate, if not offset by future revenue or partnership funding, could pressure the company’s cash position over time despite the current $352.3 million reserve.
• ●The company’s lead asset, BGE-102, is still in Phase 2 trials, with no topline efficacy data available until late 2026 or 2027. This exposes investors to significant clinical development risk, as failure in these trials would materially impact the company’s prospects.
• ●Collaboration revenue declined sharply due to a one-time accounting adjustment tied to the Novartis agreement, highlighting the unpredictability of milestone and research funding from partners. Future revenue from collaborations is not assured and may remain volatile.
• ●The company’s pipeline beyond BGE-102, including the APJ agonist programs, remains preclinical, with no disclosed clinical milestones or data. Progress and value creation from these assets are highly speculative at this stage.
• ●BioAge’s ability to sustain its projected cash runway through 2029 assumes no acceleration in spending or unforeseen setbacks. Any increase in trial costs, delays, or negative data could shorten this runway and necessitate additional financing.

Bottom line

BioAge Labs is spending aggressively to advance its lead drug BGE-102, with R&D expenses up $11.7 million year-over-year and a quarterly net loss of $33.5 million. The company is making tangible clinical progress, having dosed the first patient in its diabetic macular edema Phase 2 trial and completed enrollment in its cardiovascular Phase 2 trial, but topline results for these studies are months to over a year away. Despite sharply lower collaboration revenue this quarter, BioAge’s $352.3 million cash position provides a multi-year operational runway, with management estimating funding through 2029. The key risk is that all major value drivers hinge on future clinical data, and the current burn rate leaves little margin for error if trials disappoint or costs rise. Investors should focus on the upcoming QUELL-CV Phase 2 data in late 2026 as the next major catalyst, while recognizing that the company’s financial trajectory is negative until clinical or partnership milestones deliver new value.

Announcement summary

(NASDAQ:BIOA) BioAge Labs, Inc. reported business updates and third quarter 2026 financial results. The company’s lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. In September 2026, BioAge dosed the first participant in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema; the trial will enroll approximately 180 participants randomized 1:1:1 across three arms, with topline results anticipated in the second half of 2027. The primary endpoint for QUELL-DME is change from baseline in best-corrected visual acuity at week 12. The QUELL-CV Phase 2 trial, a randomized, double-blind, placebo-controlled dose-ranging study of BGE-102 in adults with obesity and elevated baseline inflammation, has completed enrollment of approximately 160 participants; topline data are anticipated in the fourth quarter of 2026. In Phase 1, BGE-102 achieved up to 98% suppression of IL-1β at trough and median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily. BioAge continues to advance its oral and injectable APJ agonist programs as an exercise-mimetic approach to obesity and intends to file its first IND for an APJ program by year-end 2026. The company’s multi-year research collaboration with Novartis continued to advance, with a September 2026 amendment adding $0.9 million of research funding and expanding research activities. BioAge also progressed its strategic collaboration with Lilly ExploR&D and reached the first milestone in its AI-driven drug discovery collaboration with Deep Origin in October 2026. Collaboration revenue was $0.3 million for the quarter ended September 30, 2026, compared to $2.1 million for the same period in 2025, with the $1.8 million decrease primarily due to a $1.7 million cumulative catch-up adjustment related to the Novartis Agreement amendment. Research and development expenses were $30.2 million for the quarter, up from $18.5 million in 2025, with the $11.7 million increase mainly attributable to a $13.2 million increase in direct costs related to BGE-102 clinical trials and manufacturing, and a $1.7 million increase in personnel-related expenses, partially offset by a $3.3 million decrease in direct costs for other programs. General and administrative expenses were $7.5 million, compared to $6.7 million in 2025, with the $0.8 million increase driven by a $1.2 million increase in personnel-related expenses and a $0.2 million increase in consulting fees, partially offset by a $0.6 million decrease in legal fees. Net loss was $33.5 million for the quarter, or $0.73 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $20.2 million, or $0.56 per share, for the same period in 2025. As of September 30, 2026, BioAge had approximately $352.3 million in cash, cash equivalents, and marketable securities. The company estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.

Disagree with this article?